John T. Cole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
John T. Cole has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Alexander Tremont
Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA
1 shared publicationJonathan Lu
Department of Hematology and Oncology, Ochsner Clinic Foundation, New Orleans, LA
1 shared publication
Latest Publications
- 1 December 2017
- Vol. 17 (4) , 405-411
Endocrine Therapy for Early Breast Cancer: Updated Review
Background: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. Methods: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. Results: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival. Conclusion: With the implementation of such therapies resulting in decreased mortality, patients with breast cancer are living longer than ever before. The focus of research is now directed toward the length of treatment and prediction models for recurrence.
- 1 December 2017
- Vol. 17 (4) , 405-411
Endocrine Therapy for Early Breast Cancer: Updated Review
Background: Although breast cancer is still the second most common cause of cancer-related deaths, breast cancer mortality has been declining because of advances in the use of adjuvant therapies. Methods: We summarize clinical trials involving endocrine therapies used to treat early breast cancer and discuss their inception and recent advances. Results: Endocrine therapies such as tamoxifen have revolutionized the treatment of breast cancer, resulting in significant decreases in cancer-related mortality. Aromatase inhibitors such as anastrozole and letrozole have further improved breast cancer survival. Conclusion: With the implementation of such therapies resulting in decreased mortality, patients with breast cancer are living longer than ever before. The focus of research is now directed toward the length of treatment and prediction models for recurrence.